arrow
L

Liliana Preoțescu

National Institute for Infectious Diseases
H指数:21
被引数:6,628

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Antiretroviral Activity, Pharmacokinetics, and Safety of MK-8527, an Oral Nucleoside Reverse Transcriptase Translocation Inhibitor, in Adults Living With HIV-1 Who Had Not Previously Taken Antiretroviral Agents: Results From Two Open-Label, Phase 1 Studies

抗逆转录病毒活性、药代动力学和安全性:MK-8527(一种口服核苷逆转录酶转位抑制剂)在未接受过抗逆转录病毒治疗的HIV-1感染者成人中的研究,结果来自两项开放标签的I期研究

2026-03-140
OA
A Phase III Randomized Controlled Trial of Plitidepsin, a Marine-Derived Compound, in Hospitalized Adults With Moderate COVID-19
2024-08-262
OAAI
Mapping age- and sex-specific HIV prevalence in adults in sub-Saharan Africa, 2000-2018

绘制2000至2018撒哈拉以南非洲成年人特定年龄和性别的HIV流行率

2022-12-1923
OAAI
A Randomized Clinical Trial of Regdanvimab in High-Risk Patients With Mild-to-Moderate Coronavirus Disease 2019
2022-08-0816
OAAI
Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019
2022-02-0236
OAAI
Mapping subnational HIV mortality in six Latin American countries with incomplete vital registration systems

绘制生命登记系统不完整的六个拉丁美洲国家的次国家艾滋病毒死亡率

2021-01-0890
OAAI
Mapping geographical inequalities in oral rehydration therapy coverage in low-income and middle-income countries, 2000-17

2000-17低收入和中等收入国家口服补液疗法覆盖范围的地理不平等

2020-08-0122
OAAI
Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000-17: analysis for the Global Burden of Disease Study 2017

2000至17年低收入和中等收入国家儿童腹泻发病率和死亡率的地理不平等: 全球疾病负担研究2017的分析

LANCET
IF88.5
2020-06-0165
OAAI
Mapping local patterns of childhood overweight and wasting in low- and middle-income countries between 2000 and 2017

绘制低收入和中等收入国家儿童超重和消瘦的当地模式2000年和2017

2020-04-2050
OAAI
FALDAPREVIR PLUS PEGYLATED INTERFERON/RIBAVIRIN DID NOT INCREASE ANAEMIA COMPARED WITH PEGYLATED INTERFERON/RIBAVIRIN IN HCV GENOTYPE-1, TREATMENT-NAIVE PATIENTS: POOLED ANALYSIS OF PHASE III STUDIES
2014-04-010
PREAI
SILEN-C1: SUSTAINED VIROLOGIC RESPONSE (SVR) AND SAFETY OF BI201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (P/R) IN TREATMENT-NAIVE PATIENTS WITH CHRONIC GENOTYPE 1 HCV INFECTION
2011-03-019
PREAI